Brief: Anixa Biosciences And Cleveland Clinic Present Positive New Data From Phase 1 Study Of Breast Cancer Vaccine
06/12/2023 23:08
Dec 6 (Reuters) - Anixa Biosciences Inc ANIX.O :
* ANIXA BIOSCIENCES AND CLEVELAND CLINIC PRESENT POSITIVE
NEW DATA
FROM PHASE 1 STUDY OF BREAST CANCER VACCINE
* ANIXA BIOSCIENCES INC - VACCINE WAS SAFE AND WELL
TOLERATED
* ANIXA BIOSCIENCES INC - ANTIGEN-SPECIFIC T CELL RESPONSES
WERE
OBSERVED AT ALL DOSE LEVELS
Source text for Eikon: ID:nPn1zDcpga
Further company coverage: ANIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine